For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The Canadian Cancer Trials Group is seeking a Physician trained in a cancer-related specialty to join our research group as a Senior Investigator in the Investigational New Drug (IND) Program.
Dr. Michael McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology at the BC Cancer Agency (BCCA), Vancouver Cancer Centre, and a Clinical Professor in the Division of Radiation Oncology and Developmental Radiotherapeutics at University of British Columbia. He works with patients with genitourinary cancers and brain tumours. He has served as Chair of BCCA’s Palliative Care Network.
It is with great sadness that CCTG shares the news of the passing of Aldo Del Col, a valued member of the CCTG Patient Representative Committee and the Hematology Disease Site Committee. He worked tirelessly to ensure that the patient voice was part of the design and conduct of CCTG clinical trials.
The Pharmacist Network is actively seeking a volunteer as Pharmacist Representative for the Lung Disease Site Committee.
The Pharmacist Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials. Please review terms of reference at: Pharmacist Representatives on Disease Site Committees
The Award
In recognition of the critical role played by the CCTG throughout her professional career, Dr. Shepherd is giving back by sharing her Gairdner Award with the CCTG. This award, to be endowed in perpetuity, will recognize excellence in clinical trials and translational research and will be open to all qualified CCTG investigators and post graduate trainees working on CCTG research projects.Each award will be $1000 and offered twice a year.
Eligibility
Three new publications from the CCTG Committee on Economic Analysis
CCTG would like to welcome our new Senior Investigator, Dr. James Taylor.
iRECIST training has been a recommended component of immuno-oncology (IO) protocol training documentation in the CCTG Site Training Utility (STU) since 2017. We have recently updated the iRECIST training slides in STU and as of Thursday July 18, 2019, documentation of iRECIST training is now mandatory for Qualified Investigators (QI) participating on new IO trials. In addition to new studies, some recently opened/actively accruing/planned studies will also require documentation of this training for the QI. These trials are: HN9, I227, I238 and I239 (planned).
